Geneva, July 14 -- International Clinical Trials Registry received information related to the study (NCT06954480) titled 'Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer' on March 14.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Queen Mary University of London

Condition: Triple Negative Breast Cancer

Intervention: Drug: Datopotamab Deruxtecan (Dato-DXd)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2025

Target Sample Size: 140

Countries of Recruitme...